
(WOD)
World of Dypians (WOD) price prediction for 2026-2030Listed
How has World of Dypians (WOD) performed this year? What are the short-term outlooks (1 week, 1 month, 3 months) and the long-term forecast for 2026-2030? We analyze and forecast WOD's future price based on recent trends, historical data, and technical indicators such as Moving Averages (MA), RSI, and MACD. You can also use our price prediction tool to estimate potential returns by setting your target growth rate.
World of Dypians (WOD) price
Last updated: Aug 19, 2026, 16:28:33
24h high
0.004148 USD
Market cap
2.16M USD
24h low
0.003781 USD
24h volume
801.23K USD
World of Dypians (WOD) price
0.003738 USD
Date
--
Enter your expected growth for World of Dypians to calculate its future value
Current price
0.003738 USD
Momentum
Bearish
14D RSI
76.28
50D SMA
0.005539 USD
200W SMA
0.00947 USD
Fear & Greed
44
1. Weekly EMA 200
The weekly EMA 200 is a widely used bull/bear market divider and long-term trend line in crypto.
2. Daily EMA 50
3. MACD trend & reversal signals
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.